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p53Abstract Aspartame is an artiﬁcial sweetener used as an alternate for sugar in several foods and
beverages. The study reports that consumption of aspartame containing product could lead to can-
cer. However, the effect of aspartame on apoptosis process in cancer is not yet understood clearly.
HeLa cells were exposed to different concentrations (0.01–0.05 mg/ml) of aspartame for 48 h.
Cytotoxicity of aspartame on cancer cells was determined by SRB assay. The result indicates no
signiﬁcant changes on cell viability. Aspartame suppresses apoptosis process in cancer cells by
down-regulation of mRNA expression of tumor suppressor gene p53, and pro-apoptotic gene
bax. It up-regulates anti-apoptotic gene bcl-2 mRNA expression. In addition, Ki 67 and PCNA
mRNA, and protein expressions were determined. Taking all these together, we conclude that
aspartame may be a potent substance to slow-down the apoptosis process in HeLa cells. Further
works are ongoing to understand the biochemical and molecular mechanism of aspartame in cancer
cells.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Aspartame is widely used as an artiﬁcial sweetener in several
foods (Magnuson et al., 2007). It is commonly found in low
calorie beverages and desserts (Oyama et al., 2002).
Chemically, it is a dipeptide of aspartyl-phenylalanine methylester which facilitates its intestinal hydrolysis and absorption
of amino acids (aspartic acid and phenylalanine) together with
free methanol (Lipton et al., 1991). Aspartic acid and pheny-
lalanine are commonly found in natural proteins, which are
beneﬁcial under normal circumstances (Woodrow, 1984).
Consumption of aspartame has been linked with several neuro-
logical and behavioral disturbances (Humphries et al., 2008).
However, most of the results yielded inconclusive correlations.
Aspartame is distributed under several trade names and
approved by the FDA. However, the safety of aspartame
was renewed by a report suggesting that an increase in the
number of people with brain tumors might be associated with
the introduction and use of this sweetener in the USA. A study
reports that lymphomas and leukemias were induced in rats
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Saccharin is another artiﬁcial sweetener which increases inci-
dence of urinary bladder cancer at high doses in male rats.
The aim of the present study was to investigate the short-
term effect of aspartame on apoptosis in cancer cells.
2. Materials and methods
2.1. Materials
HeLa cells were obtained from American Type Culture
Collection. DMEM and MTT were provided by Sigma–
Aldrich Chemical (St Louis, Mo). Aspartame was provided
by Supelco. Fetal bovine serum (FBS), penicillin–streptomycin
and trypsin–EDTA were purchased from Gibco. Primers of
p53, bax, bcl-2, Ki 67 and PCNA were purchased from
Macro Gen (South Korea). Primary antibodies were pur-
chased from Bioscience Technology (Seoul, South Korea).
2.2. Methods
2.2.1. SRB assay for cell viability
The effect of aspartame on HeLa cells was measured by the
SRB assay (Vichai and Kirtikara, 2006). HeLa cells were
seeded at a density of 2.2 · 104 cells/well into 96-well plates
and allowed to adhere for 24 h at 37 C. Then the cells were
treated with aspartame at different concentrations (0.01–
0.05 mg/ml) for 48 h. At the end of the treatments, cells were
ﬁxed with acetone and air dried. After fully dried, each well
was added with 100% of SRB solution (0.4% w/v) and incu-
bated for 3 h at room temperature. Microplate was washed
with 1% of acetic acid and then dried under drying oven.
Stained HeLa cells were photographed. Finally, 10 mm of
Tris-base was added and kept overnight. Following completeFigure 1 Effects of various concentrations of aspartame on cell viab
into 96 well micro plates and allowed to adhere for 24 h and treated wdissolution of SRB in Tris-base, the absorbance was measured
at 540 nm.
2.2.2. qPCR
HeLa cells were cultured in T75 ﬂask and treated with aspar-
tame (0.01–0.03 mg/ml) for 48 h. Total RNA was isolated
from the control and aspartame treated samples
(Chomczynski and Mackey, 1995). The ﬁrst-strand c-DNA
was synthesized from 1 lg of the total RNA using the M-
MLV reverse transcriptase with the anchored oligo d(T)12–18
primer. qPCR was performed using a cDNA equivalent of
10 ng of total RNA from each sample with primers speciﬁc
for p53, bax, bcl-2, Ki 67, PCNA and a housekeeping gene
GAPDH. The reaction was carried out in 10 ll using SYBR
Green Master Mix (Bioneer) according to the manufacturers’
instructions. Relative ratios were calculated based on the
2DDCT method (Pfafﬂ, 2001). PCR was monitored using the
CFX96 Real-Time System (Bio-Rad).
2.2.3. Western blot analysis
HeLa cells were cultured in T75 ﬂask and treated with aspar-
tame (0.03 mg/ml) for 48 h. Control and aspartame treated
HeLa cells were washed three times with ice-cold PBS and
lysed with 10 mM Tris–HCl (pH 7.5), 100 mM NaCl, 1%
NP-40, 50 mM NaF, 2 mM EDTA (pH 8.0), 1 mM PMSF,
10 lg/ml leupeptin, 10 lg/ml aprotinin. Equal amounts of
lysate protein samples were run on SDS polyacrylamide gel,
and then transferred onto a PVDF membrane. Non-speciﬁc
binding was blocked by soaking the membrane in Tris buffered
saline-Tween (TBST) buffer that contained 5% nonfat dry
milk for 1 h. The membrane was probed overnight with an
antibody against Ki 67 and PCNA. Following washing with
TBST buffer, the membrane was incubated for 1 h with horse-
radish peroxidase conjugated goat anti-rabbit IgG. Theility. HeLa cells were seeded at seeding densities of 2 · 104 cells/ml
ith 0.01–0.05 mg/ml of aspartame for 48 h.
Aspartame and cancer 505protein levels of Ki 67 and PCNA were determined by using
enhanced chemiluminescence kit (Muthuraman et al., 2014).
3. Results and discussion
Aspartame is one of the artiﬁcial sweeteners, used in a wide
variety of foods and beverages. It was ﬁrst approved by the
US Food and Drug Administration (FDA) for use in solid foodFigure 2 Expression of p53, bax and bcl-2 in the HeLa cells. HeL
Expressions of p53, bax and bcl-2 mRNA are related to GAPDH and
mean ± SEM, n= 6. *p< 0.05.
Figure 3 Expression of Ki 67 and PCNA in the HeLa cells. HeLa
Expressions of Ki 67 and PCNA mRNA are related to GAPDH and
mean ± SEM, n= 6. *p< 0.05.in 1981 (FDA, 1981), and extended to soft drinks (FDA, 1983).
The acceptable daily intake of aspartame is 50 mg/kg body
weight (BW) in the United States, and 40 mg/kg BW in the
European Union. Even though it is widely used in several foods
and beverages, the intake of aspartame was associated with
visual impairments, high aspartate transaminase, ear buzzing,
loss of equilibrium, muscle aches, pancreatitis, depression and
high blood pressure (Woodrow, 1984).a cells were treated with 0.01–0.03 mg/ml of aspartame for 48 h.
presented as fold. Relative expression values are the normalized
cells were treated with 0.01-0.03 mg/ml of aspartame for 48 h.
presented as fold. Relative expression values are the normalized
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aspartame for 48 h. Aspartame in concentrations of 0.01–
0.05 mg/ml showed no signiﬁcant changes in cancer cells vali-
dated by the SRB assay (Fig. 1). HeLa cells exposed to differ-
ent concentrations of aspartame for 48 h showed signiﬁcant
changes in the mRNA expression of apoptotic genes such as
p53, bax, and bcl-2.
The mRNA expression level of tumor suppressor gene p53
and pro-apoptotic gene bax was signiﬁcantly down-regulated.
The mRNA expression of p53 was signiﬁcantly reduced 0.17,
0.31 and 0.45 folds at 0.01, 0.02 and 0.03 mg/ml of aspartame
treatment respectively. The mRNA expression of bax was sig-
niﬁcantly reduced 0.09, 0.2 and 0.38 folds at 0.01, 0.02 and
0.03 mg/ml of aspartame treatment respectively, whereas bcl-
2 mRNA expression signiﬁcantly upregulated 0.14, 0.29 and
0.44 folds at 0.01, 0.02 and 0.03 mg/ml of aspartame treatment
respectively (Fig. 2, *p< 0.05). The mRNA expression of Ki
67 was signiﬁcantly upregulated 0.12, 0.29 and 0.54 folds at
0.01, 0.02 and 0.03 mg/ml of aspartame treatment respectively.
The mRNA expression of PCNA was signiﬁcantly upregulated
0.26, 0.52 and 0.63 folds at 0.01, 0.02 and 0.03 mg/ml of aspar-
tame treatment respectively (Fig. 3, *p< 0.05). Protein expres-
sion of Ki 67 and PCNA was signiﬁcantly upregulated 0.33
and 0.2 folds at 0.03 mg/ml of aspartame treatment respec-
tively (Fig. 4, *p< 0.05).
A study reports that aspartame added to feed caused a
statistically signiﬁcant increase in lymphomas and leukemiaFigure 4 Expression of Ki 67 and PCNA proteins by aspartame
treatment in the HeLa cancer cells. Western blot analysis of HeLa
cancer cell extracts probed with anti-Ki 67 and PCNA.
Quantitation analysis was carried out using densitometry. Values
are expressed means ± SEM, n= 6. *p< 0.05.in female rats (Soffritti et al., 2005). The ability of cancer cells
to avoid apoptosis and propagate is the fundamental hallmark
of cancer and is a major target of cancer therapy. The key ﬁnd-
ing of our study demonstrates that aspartame slows down the
apoptosis process in cancer cells.
4. Conclusion
HeLa cells remain viable at all the concentrations of aspar-
tame. Aspartame signiﬁcantly down-regulates mRNA expres-
sion of tumor suppressor gene p53 and apoptotic gene bax in
the cancer cells. The mRNA expression of bcl-2 was signiﬁ-
cantly up-regulated in the HeLa cells. The mRNA and protein
expression of Ki 67 and PCNA were signiﬁcantly upregulated.
However, further studies are required to deﬁne the detailed
mechanism of aspartame on apoptosis and cancer cells.
Further works are ongoing to understand the molecular mech-
anism of aspartame in cancer cells.
Acknowledgements
This paper work was supported by research funds of KU
Research Professor Program of Konkuk University,
Republic of Korea.
References
Chomczynski, P., Mackey, K., 1995. Short technical report.
Modiﬁcation of the TRIZOL reagent procedure for isolation of
RNA from polysaccharide-and proteoglycan-rich sources.
Biotechniques 19, 942–945.
FDA, 1981. Aspartame commissioner’s ﬁnal decision. Fed. Reg. 46,
38285–38308.
FDA, 1983. Food additive permitted for direct addition to food for
human consumption:aspartame. Fed. Reg. 48, 31376–31382.
Humphries, P., Pretorius, E., Naude, H., 2008. Direct and indirect
cellular effects of aspartame on the brain. Eur. J. Clin. Nutr. 62,
451–462.
Lipton, W.E., Li, Y.N., Younoszai, M.K., Stegink, L.D., 1991.
Metabolism 40, 1337–1345.
Magnuson, B.A., Burdock, G.A., Doull, J., Kroes, R.M., Marsh,
G.M., Pariza, M.W., Spencer, P.S., Waddell, W.J., Walker, R.,
Williams, G.M., 2007. Aspartame: a safety elevation based on
current use levels, regulations, and toxicological and epidemiolog-
ical studies. Crit. Rev. Toxicol. 37, 629–727.
Muthuraman, P., Jeongeun, P., Eunjung, K., 2014. Aspartame
downregulates 3T3-L1 differentiation. In Vitro Cell. Dev. Biol.
Anim. 50, 851–857.
Oyama, Y., Sakai, H., Arata, T., Okano, Y., Akaike, N., Sakai, K.,
Noda, K., 2002. Cytotoxic effects of methanol, formaldehyde and
formate on dissociated rat thymocytes: a possibility of aspartame
toxicity. Cell Biol. Toxicol. 18, 43–50.
Pfafﬂ, M.W., 2001. A new mathematical model for relative quantiﬁ-
cation in real-time RT-PCR. Nucleic Acids Res. 29, e45.
Soffritti, M., Belpoggi, F., Esposti, D.D., Lambertini, L., 2005.
Aspartame induces lymphomas and leukaemias in rats. Eur. J.
Oncol. 10, 107–116.
Woodrow, C., 1984. Monte and methanol. J. Appl. Nutr. 36, 1–15.
Vichai, V., Kirtikara, K., 2006. Sulforhodamine B colorimetric assay
for cytotoxicity screening. Nat. Protoc. 1, 1112–1116.
